FDA Rejects Ivonescimab Application as Pfizer and Blackstone Announce $1.5 Billion Financing Deal

Written by

in

Summit Therapeutics received a complete response letter from the FDA regarding its lung cancer drug ivonescimab. The regulator said the drug’s progression-free survival benefits were insufficient to establish a favorable benefit-risk relationship.

Source:Home – GeneOnline News · Read Original

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *